Vireadtenofovir disoproxil
32,757 adverse event reports submitted to the FDA (2003–2026)
Top Reported Adverse Events
The most frequently reported events in association with Viread in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
- Bone Density Decreased 10,655 reports
Renal Injury 9,278 reports
Damage to the kidneys. Renal means related to the kidneys. Related to acute kidney injury and renal impairment.
Full definition in the glossary →- Skeletal Injury 8,329 reports
Chronic Kidney Disease 7,278 reports
A long-term, gradual loss of kidney function over months or years.
Full definition in the glossary →- Osteonecrosis 7,261 reports
- Bone Loss 7,071 reports
- Multiple Fractures 6,826 reports
Renal Failure 6,678 reports
A serious decline in kidney function, where the kidneys can no longer filter waste properly.
Full definition in the glossary →Osteoporosis 5,384 reports
A condition where bones become weak and more likely to break. It often appears in reports as a condition being treated.
Full definition in the glossary →- Tooth Loss 4,514 reports
Pain 3,037 reports
A general report of physical discomfort, used when no more specific location is given.
Full definition in the glossary →Emotional Distress 2,858 reports
A report of emotional suffering such as upset, worry, or anguish. If you are struggling, the 988 Suicide and Crisis Lifeline (call or text 988 in the US) is available 24 hours a day.
Full definition in the glossary →Anxiety 2,675 reports
A feeling of worry, nervousness, or unease.
Full definition in the glossary → See all drugs reporting this event →Anhedonia 2,458 reports
A reduced ability to feel pleasure or interest in activities once enjoyed.
Full definition in the glossary →- Osteopenia 2,251 reports
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Male | 19,217 |
| Female | 9,213 |
| Unknown | 78 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 487 |
| 18-34 | 2,724 |
| 35-49 | 7,061 |
| 50-64 | 7,712 |
| 65-74 | 1,434 |
| 75+ | 348 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Viread. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Other Serious | 27,015 |
| Hospitalization | 6,348 |
| Non-Serious | 1,962 |
| Death | 1,926 |
| Life-Threatening | 660 |
| Disability | 452 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Viread. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2003 | 5 |
| 2004 | 579 |
| 2005 | 638 |
| 2006 | 526 |
| 2007 | 566 |
| 2008 | 530 |
| 2009 | 573 |
| 2010 | 473 |
| 2011 | 556 |
| 2012 | 495 |
| 2013 | 530 |
| 2014 | 932 |
| 2015 | 1,213 |
| 2016 | 1,209 |
| 2017 | 1,322 |
| 2018 | 1,507 |
| 2019 | 1,937 |
| 2020 | 12,181 |
| 2021 | 2,742 |
| 2022 | 1,733 |
| 2023 | 1,093 |
| 2024 | 749 |
| 2025 | 583 |
| 2026 (partial) | 85 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Viread
In FDA adverse event reports that mention Viread, these medications appeared most often in the same report.
- Emtricitabine And Tenofovir Disoproxil (12,836 reports)
- Lamivudine (6,120 reports)
- Elvitegravir Cobicistat Emtricitabine And Tenofovir Disoproxil (4,313 reports)
- Bictegravir Emtricitabine And Tenofovir Alafenamide (4,144 reports)
- Ritonavir (3,914 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026